ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0721

Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex

Ashley Archer1, Ruth Topless2, Angelo Gaffo1, Nicola Dalbeth3, Lisa Stamp4, Philip Robinson5 and Tony Merriman2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5School of Clinical Medicine, University of Queensland, Brisbane, Australia

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, Mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death for other inflammatory arthropathies is equivocal or non-existent. Our primary objective was to assess whether certain inflammatory rheumatic diseases (IRDs) like rheumatoid arthritis (RA), ankylosing spondylitis (AS), giant cell arteritis (GCA), psoriatic arthritis (PsA), scleroderma, Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) are risk factors for diagnosis of COVID-19 and death related to COVID-19. The secondary objective was to test for sex-specific differences in the risk of death related to COVID-19 in RA and a combined cohort of other IRDs.

Methods: We used data from the UK Biobank that included 5,973 people diagnosed with RA, 1,070 with ankylosing spondylitis, 996 with giant cell arteritis, 4,976 with psoriatic arthritis, 302 with scleroderma, 1,111 with Sjögren’s syndrome, and 289 with SLE. Three logistic regression models were employed to test for association of the IRDs with death related to COVID-19 in the entire UK Biobank cohort (n=471,743): unadjusted; adjusted for demographic variables (Model 1) and adjusted by demographic variables, seventeen co-morbid diseases, and the other IRDs (Model 2). The analysis was repeated in sex-stratified cohorts for RA and for AS+PsA+scleroderma+SS+SLE.

Results: There was no evidence for association of GCA with death related to COVID-19 in any of the models (Table 1), therefore GCA was not included in the following analyses. There was strong evidence (P< 1×10-4) for association of RA, PsA and scleroderma with death in the unadjusted model, RA and scleroderma in Model 1 and only for RA in Model 2 (OR=1.9 [95% CI 1.4 ; 2.5]). In Model 2, the only other IRD associated with death was scleroderma (OR=3.1 [1.2 ; 7.7]). In sex-specific analysis, the risk of death for women with RA (OR=2.2 [1.6 ; 3.2]) was significant but not for men in Model 2 (OR=1.4 [0.9 ; 2.2]). Under the hypothesis that any sex specific effect would be common to the IRDs, and to increase power to detect any effect, we combined AS+PsA+scleroderma+SS+SLE. There was no statistically significant evidence for association with death related to COVID-19 in either females (OR=1.1 [0.7 ; 1.7]) or males (OR=1.4 [1.0 ; 2.0]).

Conclusion: We provide further evidence that RA is a risk factor for death related to COVID-19 independent of various co-morbidities. There was an increased risk in women, however this was not statistically greater than in men (the 95% CIs overlapped). There was weak evidence for association of scleroderma with death related to COVID-19 in the fully adjusted Model, and no evidence for a sex-specific effect on risk of death in five other IRDs combined. However, the non-RA analyses were limited by the lower prevalence in the UK Biobank of some of the IRDs, in particular SLE and scleroderma (< 0.1%).

Supporting image 1


Disclosures: A. Archer, None; R. Topless, None; A. Gaffo, None; N. Dalbeth, AstraZeneca, Dyve Biosciences, Horizon, Selecta, JW Pharmaceutical Corporation, PK Med, PTC Therapeutics, Protalix; L. Stamp, None; P. Robinson, Pfizer, AbbVie/Abbott, Novartis, UCB, GlaxoSmithKlein(GSK), Janssen, Eli Lilly, Kukdong, Atom Biosciences; T. Merriman, None.

To cite this abstract in AMA style:

Archer A, Topless R, Gaffo A, Dalbeth N, Stamp L, Robinson P, Merriman T. Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/inflammatory-rheumatic-disease-and-the-risk-of-death-related-to-coronavirus-disease-19-covid-19-an-analysis-of-the-uk-biobank-with-stratification-by-sex/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-rheumatic-disease-and-the-risk-of-death-related-to-coronavirus-disease-19-covid-19-an-analysis-of-the-uk-biobank-with-stratification-by-sex/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology